--- title: "NewcelX (NCEL) stock listing, news and investor profile" url: "https://aibio.space/companies/newcelx/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "NewcelX Ltd. (NASDAQ: NCEL), Switzerland. The directory classifies it as Biotechnology. Listing facts, related biotech companies and news on aibio.space." --- NCEL NewcelX Ltd. NASDAQ · Switzerland # NewcelX (NCEL) news Top story · Jul 31, 2026 · Company press release ## [NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing Private Financing Reflects Strong Investor Confidence and Supports Advancement of Lead Type 1 Diabetes Program...](https://www.sec.gov/Archives/edgar/data/1783036/000121390026083664/ea030003402ex99-1.htm) Source: [6-K filed Jul 31, 2026 on SEC EDGAR](https://www.sec.gov/Archives/edgar/data/1783036/000121390026083664/ea0300034-6k_newcelx.htm) ## Latest NewcelX news We have not published a story on NewcelX yet. When there is news, it will appear here. ## NewcelX at a glance - **Ticker**: NCEL - **Listing**: NASDAQ - **Country**: Switzerland - **Cash, Dec 31, 2025**: $2.2 million ### Related companies - [Lonza Group](https://aibio.space/companies/lonza/) SIX: LONN - [BioVersys](https://aibio.space/companies/bioversys/) SIX: BIOV - [CRISPR Therapeutics](https://aibio.space/companies/crispr-therapeutics/) NASDAQ: CRSP - [Molecular Partners](https://aibio.space/companies/molecular-partners/) SIX: MOLN - [Veraxa Biotech](https://aibio.space/companies/veraxa-biotech/) NASDAQ: VRXA - [PolyPeptide Group](https://aibio.space/companies/polypeptide/) SIX: PPGN - [MindMaze Therapeutics Holding SA](https://aibio.space/companies/mindmaze-therapeutics/) SIX: MMTX - [Siegfried Holding](https://aibio.space/companies/siegfried/) SIX: SFZN ### Also on NASDAQ - [Kiniksa Pharmaceuticals International](https://aibio.space/companies/kiniksa-pharmaceuticals-international/) KNSA - [Sunshine Biopharma](https://aibio.space/companies/sunshine-biopharma/) SBFM - [SAB Biotherapeutics](https://aibio.space/companies/sab-biotherapeutics/) SABS - [Faeth Therapeutics](https://aibio.space/companies/faeth-therapeutics/) FTH - [Liminatus Pharma](https://aibio.space/companies/liminatus-pharma/) LIMN - [Scholar Rock Holding](https://aibio.space/companies/scholar-rock/) SRRK ## NewcelX annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$1.1 million](https://www.sec.gov/Archives/edgar/data/1783036/000121390026049307/) | [$992,000](https://www.sec.gov/Archives/edgar/data/1783036/000121390026049307/) | | Net income (loss) | [-$8.3 million](https://www.sec.gov/Archives/edgar/data/1783036/000121390026049307/) | [-$7.2 million](https://www.sec.gov/Archives/edgar/data/1783036/000121390026049307/) | | Cash from operations | [-$2.8 million](https://www.sec.gov/Archives/edgar/data/1783036/000121390026049307/) | [-$1.1 million](https://www.sec.gov/Archives/edgar/data/1783036/000121390026049307/) | | Cash and equivalents | [$2.2 million](https://www.sec.gov/Archives/edgar/data/1783036/000121390026049307/) | [$650,000](https://www.sec.gov/Archives/edgar/data/1783036/000121390026049307/) | Latest balance sheet, Dec 31, 2025 (20-F): cash and equivalents $2.2 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about NewcelX What is the ticker symbol of NewcelX? NewcelX Ltd. trades under the ticker NCEL on NASDAQ. Where is NewcelX listed? NewcelX Ltd. is listed on NASDAQ. What is the SEC CIK of NewcelX? The SEC Central Index Key (CIK) for NewcelX Ltd. is 1783036. Its filings are on SEC EDGAR. How many shares does NewcelX have outstanding? 4,797,505 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-04-29. Which country or territory is NewcelX listed under? Our directory records NewcelX Ltd. under Switzerland. What does NewcelX do? Our directory classifies NewcelX Ltd. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of NewcelX? The ISIN recorded for NewcelX Ltd. is CH1442297896. Does aibio.space cover NewcelX? aibio.space lists NewcelX Ltd. among 2,820 public biotech companies and publishes its news here as stories appear. Where is NewcelX incorporated? SEC records list its state or country of incorporation as V8. Is NewcelX profitable? NewcelX Ltd. reported a net loss of $8.3 million for the fiscal year ended Dec 31, 2025, and used $2.8 million of cash in operations, per its annual report to the SEC. How much does NewcelX spend on research and development? $1.1 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does NewcelX have? $2.2 million in cash at Dec 31, 2025, per its 20-F. Is NewcelX a smaller reporting company? SEC records list NewcelX Ltd.'s filer category as: Non-accelerated filer
Emerging growth company. Where is NewcelX headquartered? SEC records list its business address as THE CIRCLE 6, ZURICH. When does NewcelX's fiscal year end? NewcelX Ltd.'s fiscal year ends on December 31, per SEC records. ## Investor discussion: NewcelX Members talk about NewcelX (NCEL). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at NewcelX, newest first. Each line links the filing it comes from. 1. 2026-09-18 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1783036/000121390026101419/ea030514101ex99-1.htm) 2. 2026-07-31 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1783036/000121390026083664/ea030003402ex99-1.htm) 3. 2026-06-15 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1783036/000121390026068524/ea029474601ex99-1.htm) 4. 2026-04-30 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1783036/000121390026049732/ea028830901ex99-1.htm) 5. 2026-04-01 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1783036/000121390026038619/ea028455201ex99-1.htm) 6. 2025-10-29 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1783036/000121390025103226/ea026288201ex99-1_nlspharma.htm) 7. 2025-10-28 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1783036/000121390025103130/ea026286901ex99-1_nlspharma.htm) 8. 2025-10-23 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1783036/000121390025101398/ea026207001ex99-1_nlspharma.htm) 9. 2025-10-10 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1783036/000121390025097887/ea026072001ex99-1_nlspharma.htm) 10. 2025-10-06 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1783036/000121390025096255/ea025985201ex99-1_nlspharm.htm) 11. 2025-09-30 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1783036/000121390025093387/ea025937501ex99-1_nlspharma.htm) 12. 2025-08-06 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1783036/000121390025072320/ea0251991-6k_nlspharma.htm) 13. 2025-07-18 Mergers Reported a merger or acquisition agreement. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1783036/000121390025065657/ea024955301ex99-1_nlspharma.htm) 14. 2025-05-01 Distress Told the SEC a periodic report would be filed late. SEC Form NT 20-F. [Source](https://www.sec.gov/Archives/edgar/data/1783036/000121390025038073/ea0240039-nt20f_nlspharma.htm) 15. 2025-03-31 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1783036/000121390025025839/ea023626501ex99-1_nlspharma.htm) 16. 2025-03-10 Mergers Reported a merger or acquisition agreement. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1783036/000121390025021978/ea023362201ex99-1_nlspharma.htm) 17. 2024-12-11 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1783036/000121390024107656/ea022202101ex99-1_nlspharma.htm) 18. 2024-11-05 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1783036/000121390024094340/ea021985301ex99-1_nlspharma.htm) 19. 2024-11-04 Mergers Reported a merger or acquisition agreement. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1783036/000121390024093752/ea021978001ex99-1_nlspharma.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:NCEL on TradingView](https://www.tradingview.com/symbols/NASDAQ-NCEL/). ## SEC filings and registration - **SEC name**: NewcelX Ltd. - **CIK**: 1783036 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: NCEL (Nasdaq) - **State or country of incorporation**: V8 - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Emerging growth company - **Business address**: THE CIRCLE 6, ZURICH - **Phone**: 41-41-618-80-00 - **Shares outstanding**: 4,797,505 as of 2025-12-31 (20-F filed 2026-04-29) - **Former names**: NLS Pharmaceutics Ltd. ### Recent filings (8-K and 6-K are the company's own announcements) - [6-K](https://www.sec.gov/Archives/edgar/data/1783036/000121390026101419/ea0305141-6k_newcelx.htm) filed 2026-09-18 - [6-K](https://www.sec.gov/Archives/edgar/data/1783036/000121390026084652/ea0300300-6k_newcelx.htm) filed 2026-08-03 - [6-K](https://www.sec.gov/Archives/edgar/data/1783036/000121390026083664/ea0300034-6k_newcelx.htm) filed 2026-07-31 - [6-K](https://www.sec.gov/Archives/edgar/data/1783036/000121390026078173/ea0297934-6k_newcelx.htm) filed 2026-07-15 - [6-K](https://www.sec.gov/Archives/edgar/data/1783036/000121390026076199/ea0297276-6k_newcelx.htm) filed 2026-07-08 - [6-K](https://www.sec.gov/Archives/edgar/data/1783036/000121390026074040/ea0296667-6k_newcelx.htm) filed 2026-07-01 - [6-K](https://www.sec.gov/Archives/edgar/data/1783036/000121390026073725/ea0296470-6k_newcelx.htm) filed 2026-06-30 - [6-K](https://www.sec.gov/Archives/edgar/data/1783036/000121390026068524/ea0294746-6k_newcelx.htm) filed 2026-06-15 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001783036), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details NewcelX Ltd. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker NCEL, recorded under Switzerland. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: NewcelX Ltd. - **Ticker**: NCEL - **Listing**: NASDAQ - **Country or territory**: Switzerland - **Business scope**: Biotechnology - **ISIN**: CH1442297896 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-NCEL/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/newcelx/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "NewcelX (NCEL) stock listing, news and investor profile", 2026-10-31, https://aibio.space/companies/newcelx/